Innate Pharma S.A.

MUN:IDDA Stock Report

Market Cap: €211.7m

Innate Pharma Management

Management criteria checks 3/4

Innate Pharma's CEO is Mondher Mahjoubi, appointed in Dec 2016, has a tenure of 6.75 years. total yearly compensation is €1.09M, comprised of 43.1% salary and 56.9% bonuses, including company stock and options. directly owns 0.64% of the company’s shares, worth €1.35M. The average tenure of the management team and the board of directors is 5.2 years and 4.8 years respectively.

Key information

Mondher Mahjoubi

Chief executive officer

€1.1m

Total compensation

CEO salary percentage43.1%
CEO tenure6.8yrs
CEO ownership0.6%
Management average tenure5.2yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mondher Mahjoubi's remuneration changed compared to Innate Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-€63m

Mar 31 2023n/an/a

-€60m

Dec 31 2022€1m€470k

-€58m

Sep 30 2022n/an/a

-€40m

Jun 30 2022n/an/a

-€22m

Mar 31 2022n/an/a

-€34m

Dec 31 2021€1m€470k

-€45m

Jun 30 2021n/an/a

-€8m

Mar 31 2021n/an/a

-€4m

Dec 31 2020€1m€470k

-€829k

Sep 30 2020n/an/a

-€54m

Jun 30 2020n/an/a

-€44m

Mar 31 2020n/an/a

-€33m

Dec 31 2019€1m€470k

€8m

Sep 30 2019n/an/a

€5m

Jun 30 2019n/an/a

€31m

Mar 31 2019n/an/a

€17m

Dec 31 2018€1m€470k

€3m

Sep 30 2018n/an/a

-€19m

Jun 30 2018n/an/a

-€40m

Mar 31 2018n/an/a

-€44m

Dec 31 2017€750k€470k

-€48m

Sep 30 2017n/an/a

-€28m

Jun 30 2017n/an/a

-€8m

Mar 31 2017n/an/a

€3m

Dec 31 2016€2kn/a

€13m

Compensation vs Market: Mondher's total compensation ($USD1.17M) is above average for companies of similar size in the German market ($USD603.52K).

Compensation vs Earnings: Mondher's compensation has been consistent with company performance over the past year.

CEO

Mondher Mahjoubi (65 yo)

6.8yrs

Tenure

€1,091,442

Compensation

Dr. Mondher Mahjoubi, M.D., serves as Chairman at PDC line Pharma SAS since June 2020. He has been the Chairman of Executive Board and Chief Executive Officer of Innate Pharma S.A. since December 30, 2016....

Leadership Team

NamePositionTenureCompensationOwnership
Herve Brailly
Co-Founder & Chairman of Supervisory Board24.7yrs€100.00k0.92%
€ 1.9m
Mondher Mahjoubi
Chairman of Executive Board & CEO6.8yrs€1.09m0.64%
€ 1.4m
Yannis Morel
Executive VP of Product Portfolio Strategy & Business Development and Member of Executive Board8.3yrs€511.78k0.19%
€ 407.1k
François Romagné
Founderno datano datano data
Eric Vivier
Founder5.7yrsno data0.23%
€ 485.7k
Marc Bonneville
Founderno datano datano data
Jean Fournié
Founderno datano datano data
Alessandro Moretta
Founderno datano datano data
Frederic Lombard
Senior VP & CFO2.4yrsno data0.0012%
€ 2.5k
Odile Belzunce
Vice President of Compliance & Operations4.7yrsno data0.050%
€ 106.1k
Henry Wheeler
Vice President of Investor Relations & Communicationless than a yearno data0.0012%
€ 2.5k
Claire de Blanquat
VP of Legal & Corporate Affairs and Secretary of the Supervisory Boardless than a yearno data0.0012%
€ 2.5k

5.2yrs

Average Tenure

54.5yo

Average Age

Experienced Management: IDDA's management team is seasoned and experienced (5.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Herve Brailly
Co-Founder & Chairman of Supervisory Board6.8yrs€100.00k0.92%
€ 1.9m
Olivier Martinez
Member of Supervisory Boardno datano datano data
Ruslan Medzhitov
Strategic Advisory Board Member4.8yrsno datano data
Gilles Brisson
Independent Member of Supervisory Board16.2yrs€30.00k0.091%
€ 192.1k
Jean-Yves Blay
Independent Member of Supervisory Board5.8yrs€20.00k0.000060%
€ 127.0
Irina Staatz-Granzer
Independent Vice Chairman of Supervisory Board14.3yrs€41.00k0.031%
€ 66.0k
Pascale Boissel
Independent Member of Supervisory Board3.3yrs€53.67k0.0012%
€ 2.6k
Miriam Merad
Chairman of Strategic Advisory Board4.8yrsno datano data
Veronique Chabernaud
Independent Member of Supervisory Board8.4yrs€51.00k0.000010%
€ 21.2
Sebastian Amigorena
Strategic Advisory Board Member4.8yrsno datano data
Aurelien Marabelle
Strategic Advisory Board Member4.8yrsno datano data
Tanguy Seiwert
Strategic Advisory Board Member4.8yrsno datano data

4.8yrs

Average Tenure

62yo

Average Age

Experienced Board: IDDA's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/09/20 01:24
End of Day Share Price 2023/06/23 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Innate Pharma S.A. is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Olga SmolentsevaBryan Garnier & Co
Yigal NochomovitzCitigroup Inc
Michael Thomas CooperEdison Investment Research